Beyond Air (XAIR) Stock Falls -23% Over 30 Days: Compliance Pressures and Next Catalysts
Key Takeaways
- Beyond Air (XAIR) shares declined approximately 23% over the past 30 days, falling from $7.49 on July 13 to $5.75 as of August 12, 2026.
- The stock posted a steeper loss of roughly 46-52% over the last quarter, reflecting persistent pressure from Nasdaq compliance concerns, a 1-for-20 reverse stock split, and ongoing cash burn.
- A sharp single-day selloff on July 14, with volume surging to over 54,000 shares, accelerated the monthly decline as post-reverse-split volatility rattled retail and institutional holders.
- Insider buying from the CEO and CFO at $5.76 per share in late July signaled management confidence, though the stock subsequently traded below those purchase levels.
- Upcoming Q1 fiscal 2027 earnings on August 13 and progress toward FDA approval of the Gen 2 LungFit system represent the next major catalysts for the stock.
Beyond Air (XAIR) Company Overview and Market Position
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, New York. The company develops and commercializes nitric oxide (NO) therapies delivered through its proprietary LungFit platform, which generates NO from ambient air — eliminating the need for traditional gas cylinders. Its flagship product, LungFit PH, is FDA-approved and CE Marked for treating persistent pulmonary hypertension of the newborn (PPHN) and has been adopted by hospitals across the United States and international markets. Beyond Air also operates through its Beyond Cancer and NeuroNOS segments, advancing ultra-high concentration NO therapy for solid tumors and preclinical programs targeting neurological conditions. Investors follow XAIR for its disruptive NO delivery technology, expanding global commercial footprint, and pipeline optionality in oncology and neurology.
Beyond Air (XAIR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, XAIR shares fell approximately 23%, sliding from a closing price of $7.49 on July 13, 2026, to $5.75 by August 12, 2026. The decline was concentrated around a high-volume capitulation event on July 14, when the stock tumbled to $5.77 on volume exceeding 54,000 shares — roughly nine times the daily average. Subsequent sessions saw the stock stabilize in the $5.00–$6.30 range before drifting lower again in early August. I also checked comparable volume patterns using Tickeron’s AI Screener to see how XAIR stacked up against other small-cap medical device names.
The quarterly performance paints an even starker picture. From mid-May to mid-August, XAIR lost between 46% and 52% of its value. This multi-month downdraft reflects the cumulative impact of Nasdaq delisting risk, the execution of a 1-for-20 reverse stock split, consistent earnings misses versus consensus estimates, and growing investor concern over the company's cash runway relative to its operating losses.
What Drove XAIR Stock Price in the Last 30 Days
Several verified factors converged to drive the 23% selloff in XAIR over the past 30 days. The most acute catalyst was the post-reverse-split trading dynamic. After the board approved a 1-for-20 reverse split to regain compliance with Nasdaq's $1.00 minimum bid price requirement, the adjusted share price experienced significant volatility. On July 14, the stock shed roughly 23% in a single session as selling pressure overwhelmed the market, with volume spiking to 54,450 shares.
Analyst sentiment also weighed on the stock. BTIG analyst Marie Thibault reiterated a Hold rating on July 10, providing no upside catalyst for the shares. Meanwhile, the company's fiscal Q4 2026 results, reported in late June, showed revenue of $1.91 million missing consensus estimates of $2.30 million, and an EPS loss of $15.40 missing the expected loss of $11.33. Although full-year fiscal 2026 revenue grew 107% year-over-year to $7.68 million, the persistent gap between reported results and Street expectations eroded confidence.
On the positive side, insider buying provided a notable counter-signal. On July 29, CEO Robert Scott Goodman purchased 34,722 shares at $5.76 (totaling approximately $200,000), and CFO Daniel Moorhead acquired 4,340 shares at the same price. These open-market purchases indicated management's belief that the stock was undervalued, though shares subsequently traded below those levels, touching a low of $5.02.
What Drove XAIR Stock Performance Over the Last Quarter
Beyond Air's quarterly decline of nearly 50% stemmed from a confluence of structural and financial headwinds. The most prominent issue was the Nasdaq listing compliance saga. After receiving a non-compliance notice for trading below the $1.00 minimum bid threshold, the company navigated a Nasdaq Hearings Panel process that ultimately granted continued listing contingent on executing a reverse stock split by July 31, 2026. The 1-for-20 reverse split was completed, mechanically adjusting the share price higher but failing to arrest the broader downtrend.
Financially, Beyond Air continued to progress commercially — fiscal 2026 revenue more than doubled to $7.68 million, gross margins swung into positive territory, and the customer renewal rate held at approximately 90%. However, the company still reported a net loss of $33.25 million for the year, with cash and marketable securities of roughly $17.3 million against $21.6 million in long-term debt. The persistent gap between commercial traction and profitability kept risk-averse investors on the sidelines, particularly as broader small-cap and pre-revenue biotech sentiment soured. I reviewed similar compliance-driven moves with Tickeron’s AI Pattern Search Engine to put the XAIR action in context.
XAIR Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for XAIR is the company's fiscal Q1 2027 earnings report, scheduled for August 13, 2026. Analysts expect revenue of approximately $1.93 million and an EPS loss of $10.80. The results and accompanying management commentary will be critical in assessing whether commercial momentum is accelerating sufficiently to narrow losses.
Beyond the earnings print, investors should closely monitor progress on the FDA PMA supplement for the Gen 2 LungFit system. Management has guided for calendar 2027 revenue of $16–$18 million, contingent on Gen 2 approval and launch — representing a potential more-than-doubling of sales. The Gen 2 system is expected to expand the U.S. total addressable market roughly fourfold to an estimated $400 million. Delays or setbacks in the regulatory process would directly threaten this guidance.
Cash runway remains a central risk. With approximately $17.3 million in cash and marketable securities versus ongoing operating losses, the company may need to access additional capital — whether through debt, equity offerings, or partnership milestones — before reaching breakeven. Finally, the stock's post-reverse-split stability and whether insider buying at $5.76 proves to be a durable support level will influence near-term sentiment. Investors should also track institutional ownership changes, short interest trends, and any new analyst initiations or rating changes in the wake of the upcoming earnings report.
AI Tools for Navigating Biotech Volatility
When evaluating names like XAIR, I often rely on Tickeron’s AI Daily Buy/Sell Signals to surface objective, data-backed signals that complement my fundamental work. These tools scan thousands of tickers in real time and help flag potential turning points without emotional bias, which is especially useful in volatile sectors like biotech.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
XAIR's Stochastic Oscillator is staying in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XAIR just turned positive on August 11, 2026. Looking at past instances where XAIR's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XAIR as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XAIR broke above its upper Bollinger Band on August 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XAIR entered a downward trend on September 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.740) is normal, around the industry mean (10.956). P/E Ratio (0.011) is within average values for comparable stocks, (69.665). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.707). XAIR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.193) is also within normal values, averaging (40.034).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the development of nitric oxide (NO) generator and delivery system.
Industry MedicalNursingServices
Advertisement